Russell Investments Group
AKRO

Russell Investments Group’s Akero Therapeutics AKRO Stock Holding History

Russell Investments Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-189,194
Closed -$8.98M – 4178
2025
Q3 		$8.98M Buy
189,194
+54,255
+40% +$2.63M 0.01% 959
2025
Q2 		$7.2M Sell
134,939
-23,336
-15% -$1.06M 0.01% 1010
2025
Q1 		$6.41M Buy
158,275
+156,223
+7,613% +$6.62M 0.01% 1025
2024
Q4 		$57.1K Sell
2,052
-141
-6% -$4.27K ﹤0.01% 2791
2024
Q3 		$62.9K Buy
2,193
+761
+53% +$19.8K ﹤0.01% 2745
2024
Q2 		$33.6K Buy
1,432
+199
+16% +$4.26K ﹤0.01% 2849
2024
Q1 		$31.1K Buy
1,233
+1,183
+2,366% +$28.4K ﹤0.01% 2725
2023
Q4 		$1.17K Buy
50
+31
+163% +$611 ﹤0.01% 3050
2023
Q3 		$961 Hold
19
– – ﹤0.01% 3342
2023
Q2 		$887 Sell
19
-82
-81% -$3.76K ﹤0.01% 3332
2023
Q1 		$3.86K Buy
+101
New +$4.5K ﹤0.01% 2967
2020
Q4 		– Sell
-11,782
Closed -$362K – 3025
2020
Q3 		$362K Sell
11,782
-865
-7% -$30.2K ﹤0.01% 2538
2020
Q2 		$314K Buy
+12,647
New +$289K ﹤0.01% 2565

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Russell Investments Group's AKRO Position: Q4 2025 in Review

Russell Investments Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 189,194 shares — an estimated $8.98M sold.

Russell Investments Group first reported a position in AKRO in Q2 2020 and held it in 13 quarters. The position peaked at $8.98M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Russell Investments Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Russell Investments Group sold 189,194 Akero Therapeutics shares in Q4 2025, an estimated $8.98M.
  • Russell Investments Group first reported a position in Akero Therapeutics in Q2 2020 and held it in 13 quarters.
  • Russell Investments Group's Akero Therapeutics position peaked at $8.98M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Russell Investments Group's 13F filing for Q4 2025, filed 17 Feb 2026.